Biofourmis Gets into Oncology with Gaido Health

Biofourmis Gets into Oncology with Gaido Health

Biofourmis, a privately held global digital therapeutics company, has moved into the oncology arena with its acquisition of Gaido Health from Takeda Pharmaceuticals (NYSE: TAK). Gaido Health is also a digital therapeutics company but exclusively focused on the oncology market. It was part of Takeda Digital Ventures, Takeda’s corporate technology investment, and incubation arm. Financial terms were not disclosed. Boston-based Biofourmis and its Biovitals platform use artificial intelligence (AI) to offer personalized, predictive care for patients. It acquired Swiss wearables firm Biovation AG in November 2019 for an undisclosed price. For Biofourmis, the Gaido Health acquisition seeks... Read More »
One Drop Adds Glucose Sensing Platform

One Drop Adds Glucose Sensing Platform

New York City-based One Drop has acquired all the assets and intellectual property of Sano Intelligence, Inc., including its continuous glucose sensing platform. One Drop is a digital health company focused on eHealth solutions for people living with diabetes and other chronic conditions. It offers a diabetes management platform with affordable and accessible care to patients via an iOS or Android smartphone. The app is available for free download worldwide. Sano Intelligence, a Silicon Valley healthcare startup, has developed a biometric sensor that can capture and transmit glucose and blood chemistry data continuously to any device. The almost decade of work put into developing the Sano... Read More »
OrthoPediatrics Buys ApiFix Ltd.

OrthoPediatrics Buys ApiFix Ltd.

Deals that were in the pipeline prior to the Covid-19 pandemic are still closing, particularly on the technology side of health care. OrthoPediatrics Corp. (NASDAQ: KIDS) announced its acquisition of Israeli orthopedic device maker ApiFix Ltd. on April 1 for approximately $36 million. OrthoPediatrics provides products to the pediatric orthopedic market, such as trauma and deformity correction, scoliosis and sports medicine, in the United States and 41 countries. It went public in October 2017, raising $52 million as a company serving the previously neglected field of children’s orthopedics and implants. Revenues in 2019 were up 59%, to $76.6 million, compared with $45.6 million for... Read More »
Align Technology Bites for Exocad Global

Align Technology Bites for Exocad Global

Align Technology, Inc. (NASDAQ: ALGN), best known for its Invisalign system, acquired exocad Global Holdings GmbH in March. The price was approximately $407 million (EUR376 million). Exocad, based in Darmstadt, Germany, is a global provider of dental CAD/CAM software market and offers fully integrated workflows to dental labs and dental practices via a broad customer base of partners, and resellers in over 150 countries. It was a portfolio company of Carlyle Europe Technology Partners. The deal has many benefits for Align. First, it strengthens Align’s digital platform that delivers tools and features for diagnostic, restorative, implant, and orthodontic workflows. It also adds exocad’s... Read More »
Orthofix Medical Adds the Fitbone Limb Lengthening System

Orthofix Medical Adds the Fitbone Limb Lengthening System

Orthofix Medical Inc. (NASDAQ: OFIX), a global medical device company focused on musculoskeletal healing products, extended its product line with a deal for the Fitbone limb lengthening system. Privately held Wittenstein SE, based in Igersheim, Germany, will get $18 million in cash and a manufacturing supply contract. The Fitbone intramedullary lengthening system is designed to lengthen femur and tibia bones. More than 3,500 cases in 15 countries have been performed with the technology. This transaction brings other potential applications of the technology, which are in preliminary development, including the Fitspine system for early onset scoliosis. Texas-based Orthofix, formerly known as... Read More »
Hot Healthcare Sectors for Investment, Growth & Consolidation in 2020

Hot Healthcare Sectors for Investment, Growth & Consolidation in 2020

Every year, starting in November, the crystal balls come out and the prognostications begin. What will the new year bring? Who or what will make out better and who or what will not? We talked with Gary Herschman, a member of Epstein Becker Green’s Healthcare and Life Sciences practice, about the healthcare sectors he and his firm are watching in 2020. Here are their predictions for 2020. Health Care M&A: What do you see as the biggest themes in the healthcare industry this year? There are a lot of moving parts, from the discovery of new drugs to the shifting attention to post-acute care. Gary Herschman: We see three key “drivers” of health industry transformation that are already... Read More »